Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors

Teresa Tapia, Susan V. Smalley, Paulina Kohen, Alex Muñoz, Luisa M. Solis, Alejandro Corvalan, Paola Faundez, Luigi Devoto, Mauricio Camus, Manuel Alvarez and Pilar Carvallo

volume 3 | issue 3

May/June 2008
Pages: 157 - 163

Purchase article for $19

Subscribe to this journal for $79/year

» Log in

Germline mutations in BRCA1 account for a low proportion of hereditary cases in diverse populations. Several efforts have been made to find new genes involved in the inheritance of breast cancer with no success until today. The participation of BRCA1 in the development of breast cancer has been proposed in several studies where hypermethylation of its promoter and a decrease in expression has been reported for sporadic cases and one study on familial cases. To explore the participation of BRCA1 in hereditary carcinogenesis through a different mechanism than the inheritance of germline mutations, we studied the methylation status of its promoter in breast tumors, from patients previously screened for BRCA1/BRCA2 germline mutations. We also determined the presence of the BRCA1 protein in these tumors and correlated both events with tumor grade, hormone receptors and ERBB2 presence. Promoter hypermethylation of the BRCA1 gene was detected in 51% of our biopsies, among which 67% did not express the respective protein. This result leads us to suggest that hypermethylation could be considered as an inactivating mechanism for BRCA1 expression, either as a first or second hit. Moreover, a number of biopsies with absence of expression on BRCA1 showed negative detection of estrogen and progesterone receptors, a similar phenotype to BRCA1 mutated breast tumors.